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A B S T R A C T
We describe the synthesis and characterization of melanin-like nanoparticles (MNP) as novel contrast
agents for optoacoustic tomography. Good dispersion stability of high concentration MNPs in different
biological media was achieved with thiol-terminated methoxy-poly(ethylene glycol), which can be used
for further functional conjugation. MNP-PEG were found biocompatible with human MCF-7 and 3T3
cells. Cell toxicity of MNPs was found lower than that of gold nanorods for concentrations that provide
equal optical absorbance. Optoacoustic tomography images were obtained with Laser Optoacoustic
Imaging System (LOIS-3D) from tubes ﬁlled with contrast agents and live mice. Imaging of tubes
permitted veriﬁcation of the system resolution <300 mm and sensitivity Dma=0.03/cm under safe laser
ﬂuence of 20 mJ/cm2. Water suspensions of MNP demonstrated optoacoustic efﬁciency that is about
equal to that of gold nanorods under conditions of equal optical absorption. We conclude that MNPs have
the potential for biomedical imaging applications as optoacoustic contrast agents.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Optoacoustic tomography (OAT) is a biomedical imaging
modality that combines the spectral selectivity and the high
optical contrast based on variation of optical absorption with the
high resolution based on detection of ultrasound generated in
tissues with nanosecond laser pulses [1,2]. Typically, lasers emitting
in the near-infrared (NIR) spectral range from 700 nm to
1300 nm are used for generation of OA signals (and images)
due to the relatively weak absorption of biological tissues in this
spectral range, also known as the window of optical tissue
transparency [3]. Even though OAT resolution is scalable with
approximate ratio of depth of imaging to resolution of about 200 [4],
the most signiﬁcant value of this technology is expected from its
capability of visualizing deep tissue structures [5–8] and potentially
providing high contrast, high resolution quantitative volumetric
information about molecular content of biological tissues.
Hemoglobin and oxy-hemoglobin of blood are the main tissue
chromophores in the NIR spectral range [9], therefore OAT may be
naturally deﬁned as a functional imaging modality for characteri-
zation of blood distribution in the live body. On the other hand, not
many molecules of biomedical interest possess strong optical* Corresponding author.
E-mail address: aao@tomowave.com (A.A. Oraevsky).
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application of contrast agents (CA) that target non-absorbing
molecules and cells is important for molecular optoacoustic
imaging. A large number of optical and optoacoustic CA has been
developed since early 2000s, and many of them found applications
in preclinical research using live animal models [10]. The signal
amplitude emitted by a contrast agent is proportional to its volume
accumulated at the target site. Therefore, nanoparticles, such as gold
nanorods, having their volume and the optical absorption coefﬁcient
much larger than those of any molecular probe, are thought to be of
especially signiﬁcant value as contrast agents for optoacoustic
imaging [11]. All nanoparticle based optoacoustic CA can be divided
in two groups: nanoparticles based on exogenous or endogenous
chromophores. While CA development in the previous decade was
focused on exogenous nanoparticles, recently the deserved atten-
tion is gradually shifting towards less toxic nanoparticles based on
endogenous molecules [12]. Two of the biggest advantages of using
endogenous contrast agents for imaging applications are safety and
the possibility of revealing the true physiological conditions,
because the physiological parameters are not altered during
optoacoustic image acquisition.
1.1. Optoacoustic contrast opportunity offered by Melanin
Melanin molecules have much stronger optical absorption than
surrounding skin in the near-infrared region [13]. However, unlikerticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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used for biomedical diagnostics, with exception of assessment of
skin protection from ultraviolet radiation. We would like to employ
strong NIR absorption of melanin to enhance optoacoustic contrast
of tissues, such as cancerous tumors, which can potentially
accumulate signiﬁcant concentration of melanin nanoparticles.
The broad optical absorption spectrum of melanin makes it suitable
for optoacoustic imaging with any available laser wavelength
[14]. Melanins (may be surprisingly) are widely distributed in many
parts of living organisms. Melanins are involved in various functions,
including photosensitization, metal ion chelation, thermoregula-
tion, protection from radiation and free radical quenching, a vital
property in the regulation of oxidative stress [15,16]. Melanins are
usually categorized into two major types according to the difference
in precursors and colors: brown-black eumelanins and yellow-red
pheomelanins [17]. Unlike ﬂuorescent proteins, melanin cannot be
used for studies of subcellular protein distribution and interaction
analysis, but it has the advantage of being visible by such
noninvasive deep tissue imaging as optoacoustics. An advantage
of melanin compared with ﬂuorescent proteins is its very good
stability in physiological environment of live animals [18].
Previously, optoacoustic imaging has been used to detect
melanin in lymph node metastases from melanoma cancer.
Differentiation between blood and melanoma proved to be difﬁcult
because both are strong optical absorbers and therefore create
comparable optoacoustic signals [19]. OAT was previously
proposed for diagnosis, prognosis, and treatment planning of
melanotic melanoma (>90% of all melanomas) [20]. Several groups
successfully demonstrated gene delivery technique for over-
expression of melanin in cells loaded with tyrosinase, which
resulted in melanin contrast for optoacoustic (photoacoustic)
microscopy [21,22]. Melanin was also shown to be a suitable target
for laser-induced thermotherapy [18]. The tyrosinase gene can be
utilized as a multifunctional reporter gene for optoacoustic,
magnetic resonance and positron emission tomography in vitro
and in vivo [23]. On the other hand, the process of melanin
production in transfected cells is quite toxic [24]. For example,
epidermal melanocytes are particularly vulnerable to oxidative
stress owing to the pro-oxidant state generated during melanin
synthesis, and to the intrinsic antioxidant defenses that are
compromised in pathologic conditions. Melanin synthesis involves
oxidation reactions and superoxide anion (O2
) and hydrogen
peroxide (H2O2) generation, which subject melanocytes to
oxidative stress [25]. Therefore, we support promising application
of melanin as a contrast agent formulated as nanoparticles.
Melanin is an effective scavenger of free radical toxicity.
Application of melanin-based nanoparticles has been demonstrat-
ed as a protective agent against GNR induced neurotoxicity in mice
[26], against ionizing radiation [27] and, thus, MNP may be used as
a contrast and protection nanoplatform for different imaging
modalities [28]. There are usually two approaches toward
fabrication of melanin nanoparticles: nanoparticle formation from
melanin isolated from natural sources and synthesis of an artiﬁcial
MNPs. Natural melanins have been obtained by separation and
puriﬁcation of the pigment from their biological environment and
these procedures need to be developed to obtain the unmodiﬁed
characteristics of natural melanins [29]. Synthetic melanin models
are usually prepared by chemical oxidation of dopamine [30] or
enzymatic oxidation of precursor molecules such as tyrosine and
3,4-dihydroxy-L-phenylalanine. While physical and chemical
properties of melanin are preserved in the process of fabrication,
synthetic melanin models usually could not provide the particle
shape and were insoluble in water [31]. However, in the past
several years there have been developments in synthetic methods
to prepare size-controllable melanin-like nanoparticles having a
good dispersibility in water and biological media [29,32,33]. Highdispersibility and dispersion stability of nanoparticles is critically
important for two aspects of in vivo applications. The ﬁrst,
administration of the contrast agents has to be made in
signiﬁcantly enhanced concentrations in order to make their
optical absorbance competitive with red blood cells. The second
aspect is that effective PEGylation of nanoparticles needed for high
MNP dispersibility in biological media simultaneously make these
nanoparticles invisible to reticulo-endothelial system [34].
Our report is focused on three MNP-related aspects: (i) the
dispersion stability of MNP-PEG conjugates, (ii) the toxicity of PEG-
MNP conjugates in different cell cultures and in vivo and (iii) the
investigation of MNP as a contrast agent for optoacoustic imaging.
2. Materials and methods
2.1. Reagents
The chemicals were obtained at the highest purity available and
used as received from commercial sources: dopamine hydrochlo-
ride (Sigma Aldrich), sodium hydroxide (NaOH, Sigma), hexadecyl-
trimethylammonium bromide (CTAB, Sigma), ammonia hydroxide
(NH4OH, Sigma-Aldrich), potassium carbonate (K2CO3, Sigma-
Aldrich), poly (ethylene glycol) methyl either thiol or methox-
ypolyethylene glycol thiol mPEG thiol, MW 5000, (mPEG-Thiol or
PEG, Laysan Bio Inc.), gold(III) chloride trihydrate or chloroauric
acid trihydrate (HAuCl43H2O, Aldrich), sodium borohydride
(NaBH4, Aldrich), silver nitrate (AgNO3, Sigma- Aldrich). Ultrapure
water (18.2 MVcm at 25 8C) was used throughout the work.
2.2. Synthesis of Water Dispersible MNPs.
Water-dispersible MNP were prepared according to the
protocol described originally described in [29] by an oxidation
and polymerization of 3,4-dihydroxy-phenylalanin (DOPA) with
KMnO4 [32]. A total of 50 mg dopamine hydrochloride was
dissolved in 20 mL of deionized water. Under vigorous stirring,
40 to 400 mL of 1 N NaOH was added to a dopamine hydrochloride
solution at 60 8C. Instead of originally proposed 4 hours [29], we
kept the reaction overnight at pH=10 and achieved a more
homogeneous distribution of MNPs. The experiments were
conducted with 200 mL of sodium hydroxide. The color of the
solution turned to pale yellow as soon as NaOH was added and
gradually changed from transparent light to very dark brown. After
reacting overnight, MNPs were retrieved by dual centrifugation. In
contrast to original single centrifugation, we ﬁrst used low-speed
centrifugation (2500 g, 10 min) and collected supernatant dis-
carding pellet of heavy large-sized aggregated materials. Then we
performed a high-speed centrifugation (16000 g, 20 min, RT),
collected the pellet and washed it twice with deionized water. To
increase the working concentration of the MNP solution, high
speed centrifugation (16000 g, 20 min) could be repeated.
2.3. Surface Modiﬁcation of MNP by PEGylation.
For optimization of PEGylation of MNP, using our previous
experience with gold nanorods (GNR) [34], we modiﬁed the
PEGylation method previously reported in [33]. To achieve a better
PEGylation, 1.0 mL of 2 mM potassium carbonate (K2CO3) was
added to 8 mL of aqueous MNP solution (0.5 mg/mL of water), and
1.0 mL of mPEG-Thiol-5000 (molecular weight 5000, Laysan Bio
Inc.) was added in concentration 10 mM (i.e. C=5.0 mg/mL).
NH4OH solution (28 wt %) was added to adjust the pH to between
9 and 10 to stabilize the reactive medium [29]. In accord with our
previous studies [34], in the ﬁnal stage of PEGylation we added
K2CO3 to activate SH group of mPEG-Thiol molecule in order to
achieve better binding to the surface of the nanoparticle. After
Figure 1. A photograph of three dimensional laser optoacoustic imaging system
with detailed rendering of the imaging module, which include: 1 – quad ﬁber optic
bundle of the light delivery system, 2 – arc array of ultrasonic transducers, 3 –
computer controlled rotational stage, 4 – video camera.
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obtained at two cycles of centrifugation – washing. Centrifugation
was done at 16000 g for 15-20 min. The pellet was re-suspended in
phosphate buffer solution (PBS) with neutral pH=7.4.
TEM images of MNP were obtained with high contrast
transmission electron microscope JEOL 1230. In order to measure
spectral properties of nanoparticles in the spectral range of 400 –
1100 nm we used UV-VIS-NIR Spectrophotometer Evolution-201
(Thermo Fisher Scientiﬁc, New Hampshire).
2.4. Gold Nanorods (GNR) as reference nanoparticles
The general strategy for the synthesis and stabilization of GNRs
with thiol-terminal polyethylene glycol (mPEG-thiol) was adapted
from our previously reported methodologies, where we used the
displacement of the original bilayer of surfactant CTAB to provide
biocompatibility of the resulting optoacoustic contrast agent with
a narrow-band of optical absorption in the near-infrared spectral
range [34,35].
2.5. In vitro cyto-toxicity, cell viability and cell proliferation tests
Two human cells lines were used for cyto-toxicity, cell viability
and cell proliferation. These were MCF-7 (Human breast adeno-
carcinoma), and 3T3 cells (mouse embryonic ﬁbroblasts). Cell lines
were purchased from American Type Culture Collection (ATCC,
Manassas, VA, USA) and were cultured in essential media with 10%
fetal bovine serum (Hyclone) at 37.0 8C, 95% air and 5% carbon
dioxide, with renewal of the medium every 2-3 days.
Cell toxicity and cell viability were measured using the LDH and
MTT kits according to the procedure in the manufacturer’s manual
[36]. MCF-7 cells were seeded into a 96-well plate at a density of
105 cells/ml in 0.125 ml of media per well. 3T3 cells were seeded in
same plate, but at density of 5  104 cells/ml. After 24 h incubation
with gradually increasing concentrations of PEGylated MNP, 25 mL
samples of the media were collected at indicated arch indepen-
dence points in the LDH assay kit. The experimental condition was
measured using the maximum amount of releasable LDH enzyme
activity (Total or High LDH), which was determined by lysis of the
cells in the medium with 1% Triton X-100 (at this concentration,
Triton X-100 does not affect the LDH activity).
Cytotoxicity (%) was calculated as the ratio between LDH
release from cells to medium (LDHR) to the total level of LDHT after
Triton X100 application plus LDHR for each experimental condition
of PEG-MNP incubation [34].
The MTT assay is a colorimetric assay for assessing cell
viability. NAD(P)H-dependent cellular oxidoreductase is capable
of reducing the tetrazolium dye 3-(4.5 dimethylthiazol 2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to its insoluble (E,Z)-5-(4.5
dimethylthiazol 2-yl)-1,3-diphenylformazan (Formazan), which
has a purple color.
The absorbance of each well was measured with a necessary
reference by using a microplate reader ELx800TM (Bio-Tek
Instruments, VT), as described in the manuals for LDH and MTT
assays. Each experiment was performed minimum in triplicate. As
control, we used cells to which only PBS solution (pH 7.4) was
added and as a background control we used media only.
2.6. Optoacoustic imaging system
Depicted in Figure 1 is the Laser Optoacoustic Imaging System,
LOIS-3D (TomoWave Systems, Houston, TX), a commercial device
for optoacoustic tomography research in small animals, was
developed based on the laboratory prototype of TomoWave
Laboratories, described in our earlier publications [6,37–39]. A
q-switched Nd:YAG pumped Ti:Sapphire laser (SpectraWave-1x, acollaborative product of TomoWave, Houston, Texas and Quanta
Systems, Solbiate Olona, Italy) provides 8 ns pulses with energy of
50 to 100 mJ wavelengths tunable from 750 nm to 850 nm as well
as 1064 nm. For these experiments, the laser was set to 800 nm
with a repetition rate of 10 Hz. The laser pulses were delivered to
the object of imaging via double-bifurcated ﬁber bundle with 50%
losses from its circular input to rectangular outputs placed on the
surface of the imaging module at 45 and 90 degrees with respect to
the detector array of 96 ultrasonic transducers (see Figure 1). This
illumination geometry permitted close to homogeneous optical
energy distribution through the object and imaging free of skin
related artifacts. The arc shaped array of ultrawide-band ultrasonic
transducers (bandwidth of 50 kHz to 8 MHz at -6 dB) provided an
aperture of 115 deg with a radius of 65 mm, which resulted in
spatial resolution better than 0.3 mm over the volume of 40 mm
sphere. The optoacoustic coupling medium during scans was a
degassed distilled water held with a thermostat at a constant
temperature of 33 8C. Optoacoustic images were acquired by
rotating the object 360 deg with steps of 1.2 deg using computer
controlled rotational stage. The detected signals were digitized
with a sampling rate of 40 MHz. Signal processing was similar to
that described in our previous publications using deconvolution of
transducer impulse response and a band pass ﬁlter [40]. Image
reconstruction was made with ﬁltered back projection algorithm
utilizing half-time data set [41]. Three-dimensional visualization
was done with TomoView, software package developed at
TomoWave based on the open SDK source developed by Kitware
(Clifton Park, NY). The image processing parameters such as scalar
opacity, color mapping, and gradient opacity were held constant
between all objects and scans such that one can directly compare
the image brightness across all images in a quantitative manner
and assign their colors using a linear color palette. From lowest to
highest optoacoustic contrast is black to red with voxels deemed to
be noise colored black (transparent).
2.7. Experiments in Phantoms
Because of their strong optical absorption resonance in the near
infrared and spectral tenability based on aspect ratio, GNRs have
become the gold standard for optoacoustic contrast agents
[42,43]. Therefore, optoacoustic contrast of MNPs was compared
with that of GNRs. A custom-made bracket supported two silicone
tubes with internal diameter, internal diameter, ID=510 mm and
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nanoparticle suspension and the other was ﬁlled with MNP
suspension in water. To separate GNR tube from MNP tube on
optoacoustic images, the former had one knot and the latter had
two knots. This phantom was used to perform a series of
quantitative imaging experiments with LOIS-3D using pulsed
laser energy of about 6.25 mJ out of each of the four ﬁberoptic
illuminators, which corresponded to the total effective optical
ﬂuence of 2.5 mJ/cm2. Imaging experiments were repeated three
times. The average brightness of optoacoustic images was
measured in the central area of the images illuminated more
evenly than the adjacent areas. The measurement of brightness in
the tubes was done using the system’s segmentation software.
Each tube was identiﬁed and their mean brightness and standard
deviations were calculated based on their image brightness values
from the central area of the images, i.e. in the knot area of GNR tube
and in the straight portion of the MNP tube between the knots.
2.8. Experiments with a live mouse
To test toxicity of MNP in vivo we used an Athymic Nude-
Foxn1nu mouse (Harlan, Indianapolis, Indiana), 8 weeks old,
weighing about 29 g. Animal handling, isoﬂurane anesthesia,
and euthanasia were described in detail in our previous publica-
tions [37–40]. All mouse related procedures were in compliance
with our Institutional Animal Care and Use Committee (IACUC)
protocol. The mouse was illuminated with 4 laser beams each
providing the effective optical ﬂuence on the skin of 0.63 mJ/
cm2. The mouse was scanned prior to injection of MNP solution to
provide the control optoacoustic images. After the control scan, the
mouse was taken out of the imaging module and had 0.2 mL of the
melanin nanoparticles suspension in PBS with concentration of
about 30 mg MNP/mL injected intravenously through a tail vein.
The mouse was placed back in its cage after the imaging
experiment and received normal diet and water.
3. Results and Discussion
3.1. Synthesis and PEGylation of Melanin nanoparticles
The protocol of MNP synthesis by neutralization of dopamine
hydrochloride solution with sodium hydroxide by auto-oxidation
is illustrated in Figure 2. After overnight synthesis (12 hours) the
MNP were puriﬁed through several centrifugation/redispersion
cycles in deionized water to increase the uniformity of the MNP
fraction. This process allowed us to obtain 0.37 mg/ml of MNP.
Formation of melanin nanoparticles synthesized by neutralization
of dopamine hydrochloride with sodium hydroxide, or with
oxidation DOPA with KMnO4, has been veriﬁed by transmission
electron microscopy (TEM) and NIR spectroscopy. TEM images
showed the size of 4812 nm and spherical shape of generated
melanin-like nanoparticles before (Figure 3a) and after PEGylation
(Figure 3b).
We developed a protocol that improves the conjugation process
of PEG to MNP. A signiﬁcant part of this protocol consists of the
puriﬁcation of MNP stock solution. Our modiﬁed protocol of
PEGylation required a higher ratio of PEG/MNP and activation of
process through potassium carbonate, K2CO3. The amount of mPEGFigure 2. Scheme of the protocol for synthesis of melanthiol, which we used for binding to the MNPs, was 5 mg/mL for
MNP solutions in concentration 150 mg/mL. PEG covered MNP
does not have any morphological changes, which is demonstrated
by comparison of Figure 3a and 3b. Pegylation of MNP was done for
several important reasons. Pegylation is necessary for any in vivo
application of MNP, because without it the MNPs would be
recognized in the reticuloendothelial system (RES) or macrophage
system and accumulate in liver and spleen, before reaching its
destination or region of interest. PEG-MNP demonstrated strong
stability (up to several weeks) in NaCl, PBS and fetal bovine serum
solutions, where native MNP precipitated in several days.
UV-VIS-NIR absorption spectra presented for MNP after
centrifugation with different speed followed by their PEGylation
is shown in Figure 3c. Even though synthetic melanins are
insoluble in water, we achieved excellent dispersion of MNPs in
water using PEGylation. The surface of MNP can be effectively
modiﬁed with thiol-terminated methoxy-poly (ethylene glycol),
abbreviated as mPEG-SH with reaction between terminal thiol
groups and the catechol/quinine groups of the polydopamine.
Surface-modiﬁcation of MNP was conﬁrmed by characteristic of
spectral peaks of PEG (alkyl C-H and C-O-C stretching) in literature
[29]. MNP provide surface sites for amine- and/or thiol-function-
alized molecules for a wide range of functionality for biomedical
applications and imaging.
3.2. MNP toxicity and biocompatibility
Biocompatibility of pegylation was investigated through cell
viability and proliferation using different cell lines. We used
2 different techniques to assess damage to the cell membrane, cell
toxicity and cell viability. Combined data on LDH release, MTT
conversion, and LDHR/Total LDH + LDHR were also necessary for
conﬁrmation of the PEGylation protocol.
We investigated the inﬂuence of concentrations of PEGylated
MNP on the physiological status of cell cultures. MNP toxicity and
cell viability was measured for two different human cell lines
(MCF-7 and 3T3) using LDH (Figure 4a,b) and MTT (Figure 4c,d)
assays kits (Roche) as a function of the dosage of surface-modiﬁed
melanin nanoparticles with various concentrations (from 30 to
375 mg/mL for 24 h).
The Cytotoxicity Detection Kit measures cytotoxicity and cell
lysis by detecting LDH activity released from cell, as a result of the
damage to the plasma membrane after MNP administration. MTT is
cleaved to formazan by the ‘‘succinate-tetrazolium reductase’’
system (EC 1.3.99.1), which belongs to the mitochondrial
respiratory chain and is active only in viable cells or their
metabolic activity [36]. We observed only minor differences in the
measured parameters for PEG-MNP conjugates which indicated
absence of toxic effects. More than that, for the 3T3 cell line we can
show a trend to the stimulation of cell viability (Figure 4c). Our cell
viability data for PEGylated MNPs matches well to that demon-
strated previously for HeLa cells using WST-1 assay [29,33].
Figure 4e depicts viability of breast cancer cells after their
incubation during 24 hours within substantially expanded range
of nanoparticle concentrations and related optical density (OD=1,
2, 5). Cytotoxicity was studied by MTT assay for MNP solutions in
MCF7 cell cultures, and toxicity of GNR was studied in SKBR3 cell
culture. The same OD required different concentrations of MNPin-like nanoparticles from dopamine hydrochloride.
Figure 3. TEM images of melanin nanoparticles before (a) and after surface modiﬁcation (b) with methoxy-poly(ethylene glycol)-thiol. (c) Optical absorption spectra of MNP
after synthesis without high speed centrifugation (MNP no RPM), after one or two rounds of high speed RPM (MNP+RPM and MNP+2RPM respectively) and PEGylation
(MNP+PEG).
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of 300, 600 and 1500 mg/mL for MNP and 25, 50 and 125 mg/mL for
GNR [34], respectively. In addition, data published previously
demonstrated similar toxicity of PEG-GNR, which was estimated
by alternative methods of cell viability and cell membrane damage
assays [35,44].
We demonstrated that PEG modiﬁed MNPs showed no
cytotoxicity, no decrease in cell viability and no change in
morphology of cell membranes for the concentration of MNP up
to 1,500 mg/mL. Figure 4 summarize the results, which conﬁrmed
that PEGylated MNP have practically no toxicity with 3 different
tests: LDH release, percentage of cytotoxicity (ratio LDH release
and total LDH in cells) and cell viability (MTT). Enzymatic activity
tests in vitro cell cultures cannot be performed with concentrations
higher than 375 mg/mL, because background absorbance of MNP is
too high for LDH assay to be measured with a spectrophotometer.
However, motivated to determine the true concentration at which
MNP toxicity begins, we performed an experiment using MTT
assay with MNP concentrations up to C=3 mg/mL (OD=10). We
observed the beginning of PEG-MNP cytotoxicity at MNP
concentration of 1.5 mg/mL for MCF-7 cells (corresponding
OD=5) and C=1.8 mg/mL for 3T3 cells (corresponding OD= 6).
Thus, in one experiment, carefully performed, however without
statistical signiﬁcance, we demonstrated lack of MNP toxicity in
concentrations about 4 times greater than concentrations mea-
sureable from LDH assay.
Since GNRs are widely used as optoacoustic contrast agents for
preclinical research, it is interesting to compare toxicity of GNRs
and MNPs. Let us consider MNPs having diameter of 50 nm and
GNRs having length of 50 nm and width of 15 nm. The volume each
GNR is about 8900 nm3. Mass of Au per NR is 8900 nm3  59
(Gold atoms/nm3)  197/NA (MW of Gold/Avogadro constant) 1.7  1010 mg/GNR. As we found experimentally, water
suspension of these type of GNRs with aspect ratio 3.34 has
optical density of 1.0 in the concentration of 250 pM, which
corresponds to  1.5  1011 GNR/mL or  25 mg GNR/mL [34,35].
For MNPs with OD=1 concentration is 0.3 mg/mL. There is 
3  1017 nm3 per mL and the solution contains  5.2  1012 MNP/
mL because average volume for studied MNP is 5.7104
nm3. Thereby the molar concentration value is  9109 M
(5.2  1015/NA). Therefore, concentration of MNP required to
achieve optical density OD=1 is 12 times greater than that for GNRs.
Our previous studies of toxicity of GNR on different cell lines,
such as breast cancer and non-cancer cells, leukemia cells, normal
epithelial cells, and etc. [34,35,44] demonstrated that range of
cyto-toxicity of PEGylated GNR has ranged between 50-75 mg
GNR/mL (OD=2-3). In the present study we demonstrated using
MTT assay that toxicity of MNPs begins to manifest itself at the
average concentration of about 1.5 mg/mL (OD5). Therefore,
toxicity of MNP is about 2 times lower than toxicity of GNR in
suspensions of equal optical density.
3.3. Optoacoustic contrast of MNP in vitro and in vivo
The optoacoustic contrast of synthesized MNP-PEG nanopar-
ticles was tested in phantoms and two live mice. 3D optoacoustic
tomography was applied to the visualization of tubes ﬁlled with
water suspensions of MNPs and GNRs. Prior to the imaging, the
solutions of MNP and GNR with equal optical density OD=1 at the
wavelength 800 nm (see optical absorption spectra in Figure 5a)
were prepared. Green arrow on Figure 5a indicates the wavelength
800 nm at which the optoacoustic imaging was performed.
We performed two OAT experiments to demonstrate the
optoacoustic brightness of melanin nanoparticles relative to that of
Figure 4. Dose dependence effects after 24 hours incubation MNP with MCF-7 and 3T3 cell lines on LDH release into medium and total quantity of LDH in cells after their
membranes are destroyed with Triton X100 (LDH Total), each presented as mean  SD from three independent samples per concentration. (c) Percent of cytotoxicity as a function
of nanoparticle concentration after 24 hours of MNP incubation with MCF-7 and 3T3 cell lines; (d) Cell viability according to MTT assay as a function of nanoparticle concentration
after 24 hours of MNP incubation with MCF-7 and 3T3 cell lines; (e) Viability of MCF-7 breast cancer cells measured by MTT assay as a function of optical density of MNP in water
suspension and viability of SKBR3 breast cancer cells measured by the same assay as a function optical density of GNR suspension. Concentrations that correspond to OD=1, 2 and
5 are equal to 300, 600 and 1500 mg/mL for MNP and 25, 50 and 125 mg/mL for GNR, respectively.
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MNP concentration. OA image of a phantom containing two
silicone tubes with internal diameter of 510 mm was acquired.
Figure 5b depicts an image of GNR tube having a single knot (left)
and MNP tube with two knots (right), both having equal optical
density OD=1.0. Optoacoustic contrast presented in Figure 5b
presents an average image brightness M  SD over the central area
evenly illuminated by the about equal optical ﬂuence (knot area of the
GNR tube and vertical area of the MNP tube). The imaging experiment
was repeated three times. The average pixel brightness was found
(considering experimental errors) approximately equal in both
nanoparticle suspensions (Figure 5c). Because wall thickness was
150 mm we could estimate the image resolution (d < 0.3 mm) from
the fact two tubes touching each other in the knot were well
separated (see Figure 5b).
Further, the tubes were ﬁlled with two times and four times
diluted concentrations of GNR and MNP. A linear correlation
between the nanoparticle concentration and the optoacoustic
image brightness was found (Figure 5d).
The signal to noise measurements performed in this experi-
ment permitted an estimate of the system sensitivity. The
minimum optoacoustic brightness that could be detected abovethe noise corresponded to the optical density of OD=0.1, which
corresponds to Dma=0.23/cm in the tube illuminated with
combined effective optical ﬂuence of about 2.5 mJ/cm2. Should
one apply maximum safe level of the optical ﬂuence permitted by
ANSI (20 mJ/cm2) the minimum detectable change in the optical
absorption coefﬁcient will become 0.03/cm.
To investigate the biocompatibility of MNP, we administrated
these nanoparticles in two live nude mice. PEGgylated MNP were
injected intravenously in the tail vein of each mouse with a dose of
200 mg/g of body mass, or around 6 mg/per mouse (weight 29 g).
Contrast of commonly seen organs such as spleen or spine, were
not found signiﬁcantly changed as compared with native contrast
of hemoglobin (see Figure 6). This conclusion can be understood
from the following consideration. The injected concentration of
30 mg MNP/mL which provides optical absorption of 100/cm at
800 nm. We injected 200 microliter volume, maximum volume
permitted by our animal care protocol. Sometime injection though
a tail vein is difﬁcult, so injections in two live mice that resulted in
similar optoacoustic images provided an assurance that we do not
have a problem with administration of MNPs into the animal. The
injected nanoparticles did not change the image contrast of the
main features of the optoacoustic image: spleen, kidneys,
Figure 5. (a) Optical UV-VIS-NIR absorption spectra of MNP and GNR after equilibration at the wavelength of 800 nm shown with arrow. (b) OA image of two silicone tubes of
internal diameter of 510 mm and wall thickness of 150 mm, GNR tube has a single knot (left) and MNP has two knots (right), both nanoparticle suspensions had equal optical
density of 1.0. (c) The average optoacoustic brightness M  SD of the tubes with GNR and MNP is presented as a histogram. (d) Optoacoustic image brightness of silicon tubes
internal diameter of 510 mm and wall thickness of 150 mm ﬁlled with water suspension of MNP, showing linear dependence as a function of concentration. Points on the graph
correspond to the optical density of 0.25, 0.5 and 1.0.
A. Liopo et al. / Photoacoustics 3 (2015) 35–43 41vasculature and microvasculature of the spine, possibly even
slightly reduced (see Figure 6), which could be explained by the
fact that the optical absorption of male mouse blood with
hematocrit of 38 at 800 nm is 8/cm, while 0.2 mL of MNP
suspension injected into a 29 g mouse circulatory system with
2.6 mL of blood would result in 13 times dilution yielding the
optical absorption of MNPs of 7.7/cm. We also attribute some slight
decrease of brightness to a lower ﬂuence used for the image
acquisition from 1.2 mJ/cm2 in the image acquired before injection
to 1.1 mJ/cm2 applied for post injection imaging. We need to note,
however, that the main purpose of our in vivo experiment was to
demonstrate that MNPs are non-toxic neither acutely nor longFigure 6. Dorso-ventral projection of the three-dimensional optoacoustic images of a
concentration C=30 mg/mL, which corresponds to about 200 mg/g body mass.term in concentrations that after dilution by blood in the
circulatory system of a mouse will yield optical absorption close
to that of blood. While we did not target any speciﬁc region of
interest (our nanoparticles did not have a targeting agent), we
aimed at understanding of possible biodistribution and accumula-
tion of MNPs in the mouse body. To our satisfaction, from analysis
of the optoacoustic image contrast we determined that MNPs did
not accumulate in organs such as kidneys, spleen and liver two
hours post injection, indicating that they are distributed in the
circulatory system, which should enable successful targeting of
tumors or other tissues of medical interest. Mice survived MNP
injection for over four weeks (longer period of keeping the animals live mouse before and 2 hours after intravenous injection of 0.2 mL MNPs with
A. Liopo et al. / Photoacoustics 3 (2015) 35–4342was not permitted in our animal care protocol). Considering that
toxicity of MNPs is about two times lower than that of GNRs per
unit of the optical absorption, one can potentially achieve a greater
enhancement of the optoacoustic contrast while imaging live
animals with MNPs though local accumulation in the region of
interest. Future more comprehensive studies will determine the
toxicity and mortality effects of MNPs in longitudinal studies,
which require a large number of mice for statistical inference.
4. Conclusion
We synthesized and tested a novel efﬁcient melanin
nanoparticle-based contrast agent for optoacoustic imaging.
Using a size control synthesis melanin nanoparticles with
diameter of 50 nm were produced. A specially designed PEGyla-
tion process yielded nontoxic PEG-MNP conjugates that remain
stable for at least 8 weeks in biological media, such as PBS and
serum solutions and no noticeable changes in their optical
properties were observed. Using tubing phantoms we showed
that optoacoustic efﬁciency of MNPs is similar to that of GNRs.
MNP-PEG was found non-toxic and biocompatible with human
MCF-7 and 3T3 cells with toxicity level at least 20 times lower
than that of GNR-PEG with the same concentration. Considering
that the concentration (mass of nanoparticles per mL) needed to
achieve equal OD is 12 times greater for MNP than for GNR, the
cyto-toxicity of MNPs is about 2 times lower than that of GNRs if
measured in units of [mg/mL]/OD. Therefore, one can potentially
achieve a greater enhancement of the optoacoustic contrast
while imaging live animals with MNPs. Injection of 0.2 mL of
PEG-MNPs with about maximum achievable concentration of
30 mg/mL in a live mouse resulted in no life threatening toxicity
and long lasting circulation without noticeable accumulation in
vital organs within two hours. Given the fact that MNPs are
biodegradable and GNR are not, further studies of MNPs as
optoacoustic contrast agent are warranted, especially having in
mind clinical applications.
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